Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma

Twenty-seven children with abdominal Burkitt's lymphoma (stage III), who had achieved complete remission, were entered into a prospective controlled trial of adjunct treatment with Epstein-Barr virus (EBV)-specific transfer factor (TF). Two patients treated with TF and 2 controls relapsed early...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 10; no. 5A; p. 1183
Main Authors Neequaye, J, Viza, D, Pizza, G, Levine, P H, De Vinci, C, Ablashi, D V, Biggar, R J, Nkrumah, F K
Format Journal Article
LanguageEnglish
Published Greece 01.09.1990
Subjects
Abdominal Neoplasms - therapy
Adolescent
Burkitt Lymphoma - therapy
Child
Child, Preschool
Female
Herpesvirus 4, Human - drug effects
Humans
Male
Recurrence
Transfer Factor - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Twenty-seven children with abdominal Burkitt's lymphoma (stage III), who had achieved complete remission, were entered into a prospective controlled trial of adjunct treatment with Epstein-Barr virus (EBV)-specific transfer factor (TF). Two patients treated with TF and 2 controls relapsed early (less than or equal to 12 weeks). Two out of 12 TF-treated patients and 5 out of 11 controls subsequently suffered relapses. Time to first late relapse was longer among TF-treated patients (p = 0.08), and no late relapse occurred while a patient was receiving TF treatment. Thus it seems that specific TF might be useful in the management of endemic Burkitt's lymphoma and also in the treatment of other virus-associated cancers and diseases.
ISSN:0250-7005
1791-7530